Pure Global

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects - Trial NCT04202952

Access comprehensive clinical trial information for NCT04202952 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04202952
Phase 1/2
Completed
drug
Trial Details
ClinicalTrials.gov • NCT04202952
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability， Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects

Study Focus

Chronic Hepatitis C

HEC110114 Tablet

Interventional

drug

Sponsor & Location

Sunshine Lake Pharma Co., Ltd.

Jilin, China

Timeline & Enrollment

Phase 1/2

Jul 06, 2020

Aug 27, 2020

24 participants

Primary Outcome

Adverse Events

Summary

A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending
 Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114
 Tablets in HCV-infected Subjects

ICD-10 Classifications

Chronic viral hepatitis C
Acute hepatitis C
Chronic viral hepatitis
Other chronic viral hepatitis
Chronic hepatitis, unspecified

Data Source

ClinicalTrials.gov

NCT04202952

Non-Device Trial